Beshoi from United Arab Emirates

Registered at the short selling broker eToro, 5 minutes ago.

» Try eToro you too
75% of retail investor accounts lose money when trading CFDs with etoro.
Don't show again

Eli Lilly & Co. (LLY) shares information

Lilly(Eli) & Co


24h Change

2.19 %

LLY

Live rate: Market closed

Stock data per Friday 15 Jan, 2021

LLY
NEW YORK STOCK EXCHANGE, INC.
186.69
186.8
190.77
4.08 (+ 2.19%)
US Market is closed

Live Stock price in graph for Lilly(Eli) & Co (LLY)

  • Latest Volume

    6,624,572 (50.11 %)

  • Volume prev. day

    4,413,184

  • Avg. daily volume

    3,731,947

  • Market cap

    182,487,071,450

  • P/E ratio

    31.22

  • Today high

    191.78 USD

  • Today low

    186.8 USD

  • 52 week high

    191.78 USD

  • 52 week low

    117.31 USD

  • YTD Change

    + 15.17 %

Quick links

 

Latest news about Lilly(Eli) & Co

Below you can find the most recent news posts about Lilly(Eli) & Co, primarily from US and UK based news sources.

Europe and Canada are facing temporary hits to coronavirus vaccine supply while Pfizer renovates a Belgian plant to eventually produce more doses

Friday, 15 January 2021, 21:33:05
Summary List Placement European countries and Canada will receive fewer doses of Pfizer's coronavirus vaccine than planned in the weeks ahead, an unexpected cut as Pfizer is renovating a critical manufacturing plant to eventually boost production. The disruption will happen in late January and early February, a Pfizer spokesperson told Insider. The global pharmaceutical giant is still aiming to produce 2 billion doses in 2021, and the work won't impact US supply, which comes from a facility in Kalamazoo, Michigan. Read more: What's coming next for COVID-19 vaccines? Here's the latest on 11 leading programs. Earlier this month, Pfizer boosted its 2021 supply projection from 1.3 billion to 2 billion doses. The company's vaccine, developed alongside the German biotech BioNTech, was OK'd for emergency use in the US in December . “To do this, Pfizer is scaling up manufacturing operations to increase dose availability and output,” the company spokesperson said in a statement. Changes to the production process at Pfizer's facility in Puurs, Belgium, will need regulatory signoffs, which ultimately will delay shipments over the next month.
— Business Insider


Radiopharmaceutical Market to Watch: Spotlight on SIEMENS, Jubilant Pharma, Eli Lilly, GE Healthcare

Thursday, 14 January 2021, 15:10:23
Global Radiopharmaceutical Industry Market Research Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread) is latest research study released by HTF MI evaluating the market, highlighting opportunities, risk side analysis,
— OpenPR


PureTech Founded Entity Follica Adds Two Leaders in Aesthetic Medicine and Dermatology to its Board of Directors

Thursday, 14 January 2021, 12:50:00
Bringing a depth of expertise in product registration, commercial & business development Tom Wiggans, former CEO of Dermira, joins as Executive Chairman Michael Davin, former CEO of Cynosure, joins Board of Directors PureTech Health plc ((LSE: PRTC, NASDAQ: PRTC ) (“PureTech” or the “Company”) is pleased to note that its Founded Entity, Follica, today announced the appointment of two veteran biotech executives to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210114005191/en/ Follica announced the appointment of two veteran biotech executives to its Board of Directors. Tom Wiggans, former CEO of Dermira, joins as Executive Chairman, and Michael Davin, former CEO of Cynosure, joins as an independent member. Tom Wiggans joins as Executive Chairman with over 30 years of experience leading biopharmaceutical companies from the start-up stage to global commercialization. Mr. Wiggans most recently co-founded and served as Chairman and Chief Executive Officer of Dermira, a company developing new therapies for chronic skin conditions.
— Benzinga


Follica Adds Two Leaders in Aesthetic Medicine and Dermatology to Its Board of Directors

Thursday, 14 January 2021, 12:50:00
Bringing a depth of expertise in product registration, commercial & business development Tom Wiggans, former CEO of Dermira, joins as Executive Chairman Michael Davin, former CEO of Cynosure, joins Board of Directors Follica Inc. (“Follica”) , a biotechnology company developing a regenerative platform designed to treat androgenetic alopecia, epithelial aging and other related conditions, today announced the appointment of two veteran biotech executives to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210114005208/en/ Follica announced the appointment of two veteran biotech executives to its Board of Directors. Tom Wiggans, former CEO of Dermira, joins as Executive Chairman, and Michael Davin, former CEO of Cynosure, joins as an independent member. (Photo: Business Wire) Tom Wiggans joins as Executive Chairman with over 30 years of experience leading biopharmaceutical companies from the start-up stage to global commercialization.
— Benzinga


Poultry Health Market SWOT Analysis By 2021: Bayer Healthcare, Boehringer Ingelheim, Ceva Animal Health, Elanco (Eli Lilly), Merck

Wednesday, 13 January 2021, 12:12:41
Poultry Health market competitive insights provide details by a competitor. Details included are market overview, company financials, revenue generated, market potential, Porter’s analysis, investment in research and development, drivers and restraints, new market initiatives, company strengths, overview, and weaknesses, regional
— OpenPR


Trading broker recommendation

We recommend that you check out Capital.com as they have a very good selection of stocks available for both going short and long.

Rating: 9.57/10
Minimum deposit: €200
Description: Capital.com offer a large number of stocks for trading. Register an account today and check if they have LLY available or trade one of the many other CFD stocks they have.
Risk warning: 75% of retail investor accounts lose money when trading CFDs with Capital.